Novavax, Inc., CPL Biologicals and the International Centre for Genetic Engineering and Biotechnology Announce Collaboration to Develop New Malaria Vaccine With Funding From Government of India
Published: Jul 16, 2012
ROCKVILLE, Md., July 16, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), CPL Biologicals (CPLB) and the International Centre for Genetic Engineering and Biotechnology (ICGEB), today announced that they have formed a new collaboration to develop a novel malaria vaccine in India. This unique public-private partnership will combine the advanced vaccine technology of Novavax with the malaria vaccine research capabilities of ICGEB and vaccine manufacturing capability of CPLB, to develop a new and effective malaria vaccine. The project is being funded by India's Department of Biotechnology Vaccine Grand Challenge Program and will be managed by the Malaria Vaccine Development Program, a New Delhi-based not-for-profit organization established to support the development of malaria vaccines.